*Aurobindo Pharma Ltd.*
C&H Formation: Weekly Basis
Price BreakOut Done & Sustained
Strong Vol. Consolidation / Continued BuiltUp.
Resistance at 734 / 855 / 905 / 1064
*With Upside, Trail SL*
*Book Profit as per Risk Appetite*
*Snapshot*
Hyderabad based, Vertically-integrated Formulations / API manufacturer.
Has 14 formulation Mfg. facilities globally: (US: 3, Brazil: 1, Portugal: 1, India: 11 (API units).
Witnessing stronger growth in the U.S., Europe, growth markets & APIs.
New ventures on Biosimilars, Peptides, PLI are on track: Likely drive growth FY25 onwards.
Increasing Sales/Profitability on Qtrly Basis. Fluctuating on Yrly Basis
Decline in RoA/RoE/RoCE post FY21. Stable post FY22
Stable TNW / Cash Reserve / Investments.
+ve Ops. Cash Flow/.
Promoter Stake Stable. FII / DII Stake Increasing.
*Concern:*
Increased leverage. Stretched WC Cycle.
ARV segment’s revenue declined by ~32.6% y-o-y
*Do Your Own Research as Well. This is Just an Opinion.*
Happy Investing :)
C&H Formation: Weekly Basis
Price BreakOut Done & Sustained
Strong Vol. Consolidation / Continued BuiltUp.
Resistance at 734 / 855 / 905 / 1064
*With Upside, Trail SL*
*Book Profit as per Risk Appetite*
*Snapshot*
Hyderabad based, Vertically-integrated Formulations / API manufacturer.
Has 14 formulation Mfg. facilities globally: (US: 3, Brazil: 1, Portugal: 1, India: 11 (API units).
Witnessing stronger growth in the U.S., Europe, growth markets & APIs.
New ventures on Biosimilars, Peptides, PLI are on track: Likely drive growth FY25 onwards.
Increasing Sales/Profitability on Qtrly Basis. Fluctuating on Yrly Basis
Decline in RoA/RoE/RoCE post FY21. Stable post FY22
Stable TNW / Cash Reserve / Investments.
+ve Ops. Cash Flow/.
Promoter Stake Stable. FII / DII Stake Increasing.
*Concern:*
Increased leverage. Stretched WC Cycle.
ARV segment’s revenue declined by ~32.6% y-o-y
*Do Your Own Research as Well. This is Just an Opinion.*
Happy Investing :)